Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

NCT00374933 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI
DRUG: "Prophylactic" delayed ADLI
DRUG: "Prophylactic" delayed activated donor lymphocyte infusion

Sponsor

Abramson Cancer Center at Penn Medicine